We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Gene Therapy for CAD Shows Promise

By Biotechdaily staff writers
Posted on 23 May 2002
A study of a new therapeutic procedure utilizing a gene product designed to produce a protein that promotes blood vessel growth in the heart shows promise for treating patients with coronary artery disease (CAD). More...
The multicenter study, reported in the March 2002 issue of Circulation, was the first trial of intracoronary gene therapy.

Currently available treatment options for coronary artery disease include drug therapy, angioplasty and bypass surgery. A nonsurgical treatment, therapeutic angiogenesis is performed via catheterization – the insertion of a tiny tube into the blood vessels surrounding the heart in order to deliver a growth factor gene into the coronary arteries. For this experimental therapy, a product called growth factor gene is then delivered through the tube into the coronary arteries.

In the first phase of the current study, 79 patients between the ages of 30 and 75 and diagnosed with mild to moderately severe stable angina. All underwent catheterization, with 60 of the patients receiving a growth factor gene, and the remaining 19 received a placebo. None of the patients or investigators in the double-blind study knew who received the active therapy until the end of the study.

To evaluate the effectiveness of the treatment, patients underwent exercise treadmill testing at 4 weeks and 12 weeks following treatment. Patients who had received the growth factor gene, or therapeutic angiogenesis, showed a larger improvement in exercise ability than those patients in the placebo group. The therapy appeared to be safe and well tolerated with no major adverse effects.

"This research has taken an initial, but significant, step in a new direction in the treatment of coronary artery disease,” said Dr. Matthew Watkins, associate professor of medicine at the University of Vermont (Burlington, USA) and one of the lead authors. It leads towards a treatment, which does not involve a mechanical solution or standard drug therapy, that may be of particular benefit to patients with chronic angina who are not good candidates for additional angioplasty or bypass surgery. We are encouraged by these results and look forward to the findings from the Phase 3 trial.”




Related Links:
The University of Vermont

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
Prefilled Tubes
Prefilled 5.0ml Tubes
New
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study results show blood protein levels change markedly in childhood and adolescence, with sex differences increasing with age (photo credit: Adobe Stock)

Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges

Serum proteins underpin many routine tests used to detect inflammation, hormonal imbalance, cardiovascular disease, and metabolic disorders. Yet pediatric interpretation often relies on adult reference... Read more

Pathology

view channel
Image: Study flowchart. This study developed a multimodal artificial intelligence framework to predict PIK3CA mutations in breast cancer (Jiaxian Miao et al., Cancer Biol Med 23(3): 430–450 (2026). DOI: 10.20892/j.issn.2095-3941.2025.0771)

Multimodal AI Tool Predicts Genetic Alterations to Guide Breast Cancer Treatment

PIK3CA mutations are key biomarkers for selecting phosphoinositide 3-kinase (PI3K)–targeted therapies in breast cancer, yet access to molecular testing can be inconsistent and costly. Conventional polymerase... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.